Gliclazide Injectable Depot Forms: Development of Model Compounds and Efficacy Assessment

INTRODUCTION. Despite a broad range of available hypoglycemic agents, the choice of dosage forms, particularly those with prolonged release, remains limited. This necessitates the development of injectable depot formulations for the prolonged and controlled release of an active pharmaceutical ingredient. A key milestone and one of the pivotal factors in developing a stable parenteral depot formulation is testing solubility of the active pharmaceutical ingredient and selecting a solvent / solvent mixture that ensures effective release of the compound. One of the most frequently prescribed hypoglycemic agents is gliclazide, currently only available in oral dosage forms. Therefore, the development of a prolonged-release form for parenteral administration is urgent, since it will optimize therapy for a wide range of patients.

AIM. This study aimed to develop a prolonged-release depot system of gliclazide for parenteral administration.

MATERIALS AND METHODS. Gliclazide solubility in biocompatible solvents was determined according to a pharmacopeial method (under standard conditions and when heated). In vitro biopharmaceutical studies were based on dialysis with a cellophane membrane. Gliclazide in dialysate samples was quantified using UV spectrophotometry (λ=230 nm). Antidiabetic effect of the test samples was determined in male Wistar rats with an alloxan-induced diabetes model. Blood glucose was measured using an Accu-Chek® Performa Nano glucometer for 24 h after a single administration of the test samples.

RESULTS. Gliclazide solubility assessment indicated better solubility in dimethyl sulfoxide and 95% ethyl alcohol. However, gliclazide was practically insoluble in polyethylene glycol-400, propylene glycol-1,2, isopropyl myristate, glycerol, and slightly soluble in 70% ethyl alcohol. When heated, gliclazide solubility in propylene glycol-1,2 and polyethylene glycol-400 increased to slightly soluble. Gliclazide release from an aqueous suspension model over 2 h was 15.69±0.49%. Comparable antidiabetic effect was established for injection depot models using binary dispersion media based on combinations of water for injection, propylene glycol-1,2, and dimethyl sulfoxide. A more pronounced hypoglycemic effect was observed when using water for injection : propylene glycol-1,2 and dimethyl sulfoxide : propylene glycol-1,2 as a dispersion medium.

CONCLUSIONS. Model compounds have been obtained for gliclazide prolonged-release injectable depot forms based on the binary media, with a subsequent biopharmaceutical assessment. The findings necessitate the use of organic solvents in the suspension that would improve gliclazide release from the aqueous suspension.

1. Dedov II, Shestakova MV, Vikulova OK, et al. Epidemiology and key clinical and therapeutic indicators of diabetes mellitus in Russian Federation according to the World Health Organization’s strategy goals. Diabetes mellitus. 2025;28(1):4–17 (In Russ.). https://doi.org/10.14341/DM13292

2. Shestakova MV, Vikulova OK, Zheleznyakova AV, et al. Diabetes mellitus in the elderly: clinical and epidemiological characteristics of the all-Russian cohort of diabetic patients over 65 years. Diabetes mellitus. 2024;27(6):504–19 (In Russ.). https://doi.org/10.14341/DM13261

3. Yazbeck AS, Nguyen SN, Escobar ML. How health systems world-wide fail type 2 diabetics. Health Syst Reform. 2025;11(1): 2437898. https://doi.org/10.1080/23288604.2024.2437898

4. Asaad GF, Doghish AS, Rashad AA, El-Dakroury WA. Exploring cutting-edge approaches in diabetes care: from nanotechnology to personalized therapeutics. Naunyn Schmiedebergs Arch Pharmacol. 2025;398(3):2443–58. https://doi.org/10.1007/s00210-024-03532-7

5. Petunina NA, Martirosian NS, Goncharova EV, et al. The place of gliclazide MB in mo-dern treatment strategies for patients with type 2 diabetes mellitus. Diabetes mellitus. 2024;27(4):368–75 (In Russ.). https://doi.org/10.14341/DM13184

6. Savedoff W, Yazbeck AS, Peters DH, Nguyen SN. Deve-lopment assistance for health and the challenge of NCDs through the lens of type 2 diabetes. Health Syst Reform. 2025;11(1):2531693. https://doi.org/10.1080/23288604.2025.2531693

7. Sahin I, Bakiner O, Demir T, et al. Current position of gliclazide and sulfonylureas in the contemporary treatment paradigm for type 2 diabetes: a scoping review. Diabetes Ther. 2024;15(8):1687–716. https://doi.org/10.1007/s13300-024-01612-8

8. Misnikova IV, Kovaleva YuA, Gubkina VA, Dreval AV. Gliclazide MR in the structure of antihyperglycemic the-rapy according to the data of Moscow region diabetes register. Diabetes mellitus. 2022;25(2):166–73 (In Russ.). https://doi.org/10.14341/DM12799

9. Alidori S, Subramanian R, Holm R. Patient-centric long-acting injectable and implantable platforms — an industrial perspective. Mol Pharm. 2024;21(9):4238–58. https://doi.org/10.1021/acs.molpharmaceut.4c00665

10. Panchal K, Katke S, Dash SK, et al. An expanding horizon of complex injectable products: development and regulatory considerations. Drug Deliv Transl Res. 2023;13(2):433–72. https://doi.org/10.1007/s13346-022-01223-5

11. Wilkinson J, Ajulo D, Tamburrini V, et al. Lipid based intramuscular long-acting injectables: Current state of the art. Eur J Pharm Sci. 2022;178:106253. https://doi.org/10.1016/j.ejps.2022.106253

12. Zhang K, Xue K, Loh XJ. Thermo-responsive hydrogels: from recent progress to biomedical applications. Gels. 2021;7(3):77. https://doi.org/10.3390/gels7030077

13. Sushinskaya OA, Golyak NS, Tsarenkov VM. Methods for studying the release of active substances from external drug forms. Vestnik Farmatsii. 2019;4(86):86–96 (In Russ.). EDN: XHGKGO

14. Kottaisamy CPD, Raj DS, Prasanth Kumar V, Sankaran U. Experimental animal models for diabetes and its related complications-a review. Lab Anim Res. 2021;37(1):23–37. https://doi.org/10.1186/s42826-021-00101-4

15. Kim JM. Induction of diabetes mellitus using alloxan in sprague dawley rats. Cureus. 2024;16(6):e63359. https://doi.org/10.7759/cureus.63359

16. Demina NB. Biopharmaceutical classificatiom system as a tool for the development of drug formulations and their designs. Drug Development & Registration. 2017;(2):56–60 (In Russ.).

17. Ibrahim BA, Hussein NR, Omer HK, et al. Enhancing gliclazide solubility using solid dispersions with carboxymethyl chitosan and polyvinylpyrrolidone K30 as polymeric carriers. Drug Dev Ind Pharm. 2025;51(7):735–46. https://doi.org/10.1080/03639045.2025.2506651

18. Yu S, Xu X, Xing W, et al. Solubility, thermodynamic parameters, and dissolution properties of gliclazide in seventeen pure solvents at temperatures from 278.15 to 318.15 K. J Mol Liq. 2020; 312:e113425. https://doi.org/10.1016/j.molliq.2020.113425

19. Wang Z, Yu S, Li H, et al. Solid-liquid equilibrium behavior and solvent effect of gliclazide in mono- and binary solvents. ACS Omega. 2022;7(42):37663–73. https://doi.org/10.1021/acsomega.2c04540

20. Yu S, Cheng Y, Xing W, Xue F. Solubility determination and thermodynamic modelling of gliclazide in five binary solvent mixtures. J Mol Liq. 2020;311:113258. https://doi.org/10.1016/j.molliq.2020.113258

21. Storozhenko SE, Kutyakov VA, Stepanova EF, Veselova OF. Development and pharmacokinetic study of the original dosage form − gliclazide suspension. Problems of Biological, Medical and Pharmaceutical Chemistry. 2020;23(12):31−35 (In Russ.). https://doi.org/10.29296/25877313-2020-12-05